CABALETTA BIO, INC. (CABA): Price and Financial Metrics


CABALETTA BIO, INC. (CABA): $0.64

-0.01 (-1.23%)

POWR Rating

Component Grades

Growth

S

Value

I

Momentum

G

Stability

N

Sentiment

U

Quality

P

Add CABA to Watchlist
Sign Up

Industry: Biotech


Ranked

of

in industry

CABA Stock Price Chart Interactive Chart >

Price chart for CABA

CABA Price/Volume Stats

Current price $0.64 52-week high $14.95
Prev. close $0.65 52-week low $0.59
Day low $0.64 Volume 402,800
Day high $0.68 Avg. volume 565,967
50-day MA $1.13 Dividend yield N/A
200-day MA $1.87 Market Cap 18.63M

CABALETTA BIO, INC. (CABA) Company Bio


Cabaletta Bio, Inc. operates as a clinical-stage biotechnology company, which engages in the discovery and development of engineered T cell therapies for B cell-mediated autoimmune diseases. Its proprietary technology utilizes chimeric autoantibody receptor to selectively bind and eliminate B cells that produce disease-causing autoantibodies. The company was founded by Michael C. Milone, Steven Nichtberger, and Aimee Payne in 2017 and is headquartered in Philadelphia, PA.


CABA Latest News Stream


Event/Time News Detail
Loading, please wait...

CABA Latest Social Stream


Loading social stream, please wait...

View Full CABA Social Stream

Latest CABA News From Around the Web

Below are the latest news stories about CABALETTA BIO INC that investors may wish to consider to help them evaluate CABA as an investment opportunity.

Cabaletta Bio to Present at the Chardan 6th Annual Genetic Medicines Conference

PHILADELPHIA, Sept. 26, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in a fireside chat at the Chardan 6th Annual Genetic Medicines Conference on Monday, October 3, 2022 at 4:00 p.m. ET in New York, NY. A live webcast of the presentati

Yahoo | September 26, 2022

Cabaletta Bio Presents New Interim Data from the DesCAARTes™ Phase 1 Trial at the 31st EADV Congress

PHILADELPHIA, Sept. 10, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today presented updated clinical and translational data through 6 months of follow-up in cohorts A1 through A4 as well as 28-day safety data and DSG3-CAART persistence data through day 29 for cohorts A1 through A5 from the DesCAARTes™ trial at the 31st European Academy

Yahoo | September 10, 2022

Cabaletta Bio to Participate in Upcoming Investor Conferences in September

PHILADELPHIA, Sept. 06, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that the Company will participate in two upcoming investor conferences in September: Morgan Stanley 20th Annual Global Healthcare Conference: Steven Nichtberger, M.D., President and Chief Executive Officer, will participate in a fireside chat on Monday,

Yahoo | September 6, 2022

Cabaletta Bio to Present Data at the 31st EADV Congress and Provides Update on DesCAARTes™ Trial

PHILADELPHIA, Aug. 29, 2022 (GLOBE NEWSWIRE) -- Cabaletta Bio, Inc. (Nasdaq: CABA), a clinical-stage biotechnology company focused on the discovery and development of targeted cell therapies for patients with autoimmune diseases, today announced that it will present new clinical and translational data from cohort A4 and safety data from cohort A5 in the DesCAARTes™ trial of DSG3-CAART in a late-breaking oral presentation at the upcoming 31st European Academy of Dermatology and Venereology (EADV)

Yahoo | August 29, 2022

Analysts Offer Insights on Healthcare Companies: Freeline Therapeutics Holdings (FRLN), Cabaletta Bio (CABA) and Neovasc (NVCN)

There's a lot to be optimistic about in the Healthcare sector as 3 analysts just weighed in on Freeline Therapeutics Holdings (FRLN – Research Report), Cabaletta Bio (CABA – Research Report) and Neovasc (NVCN – Research Report) with bullish sentiments. Freeline Therapeutics Holdings (FRLN) H.C. Wainwright analyst Patrick Trucchio maintained a Buy rating on Freeline Therapeutics Holdings today and set a price target of $15.00. The company's shares closed last Friday at $0.95, close to its 52-week low of $0.65. According to TipRanks.

Brian Anderson on TipRanks | August 22, 2022

Read More 'CABA' Stories Here

CABA Price Returns

1-mo -35.99%
3-mo -50.00%
6-mo -68.32%
1-year -94.58%
3-year N/A
5-year N/A
YTD -83.11%
2021 -69.63%
2020 -10.67%
2019 N/A
2018 N/A
2017 N/A

Get Free Updates

Join thousands of investors who get the latest news, insights and top rated picks from StockNews.com!


Page generated in 0.5072 seconds.